Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: SOROS who wrote (811)	5/22/1998 3:24:00 AM
From: Ms. Forthright	Respond to of 1185

SOROS I joined a large brokerage firm in a meeting with Nortran yesterday. There is a lot to be enthusiastic about! Bob Reider presents very well, his knowledge regarding the biotech industry is impressive. He is really a tremendous asset to Nortran. At this point there are several projects in the pipeline: The antiarrhythmics, atrial and ventricular, these are now well known. Nociblockers. Antitussive (cough suppressant). This was discovered serendipitously, as this particular compound has already passed clinical trials for another indication. I understand that it was essentially free of adverse effects. As you may be aware dextromethorphan and its competitors are not very effective, leaving this huge market wide open. Local anesthetic. Better than lidocaine. Bread and butter stuff. Dermal anesthetic. Big market, still early. Proerectile/libido enhancement. Preclinical studies most impressive(no pun intended). Timing could not be better for licensing this compound. I expect this will be the next major accomplishment for Nortran. This is just my opinion, management would not comment about specifics.